World’s top intensive care body advises against use of remdesivir for sickest COVID-19 patients

Remdesivir Gilead

The antiviral drug remdesivir should not be used as a routine treatment for COVID-19 patients in critical care wards, the head of one of the world’s top bodies representing intensive care doctors said, in a blow to the drug developed by U.S. firm Gilead.

Leave a Reply

Your email address will not be published. Required fields are marked *